ArticleEuropean archives of psychiatry and clinical neuroscience2025
Genetic insights into the effect of Metformin on psychiatry disorders.
Article in European archives of psychiatry and clinical neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveThis study employs Mendelian Randomization (MR) to explore the causal relationships between Metformin and 20 mental illnesses. The aim is to provide new pharmacological treatment bases for the treatment and intervention of mental illnesses, thereby reducing incidence rates and alleviating the disease burden.
methodsThis study uses summarized data from Genome Wide Association Studies (GWAS) to identify genetic instrumental variables (IVs) that are significantly associated with Metformin and are mutually independent. The primary method used to evaluate causal relationships is the Inverse Variance Weighted (IVW) approach, complemented by other MR methods for sensitivity analysis.
resultsMR analysis results indicate a significant negative causal relationship between genetically predicted Metformin and Neuroticism(NEU) (OR = 0.700, 95% CI: 0.505-0.970, P = 0.032) and Bipolar Disorder(BID) (OR = 0.0374, 95% CI: 0.00266-0.525, P = 0.015). Additionally, a significant positive causal relationship was found with Attention deficit hyperactivity disorder(ADHD) (OR = 15.4, 95% CI: 1.95-122, P = 0.010) and Insomnia(INS) (OR = 1.96E + 06, 95% CI: 351-1.10E + 10, P = 0.001). There were no significant causal relationships with the remaining mental illnesses (P>0.05). Sensitivity analyses indicate that the results are robust.
conclusionFrom a genetic perspective, this study finds that Metformin may reduce the risk of NEU and BID while increasing the risk of ADHD and INS. These findings not only provide theoretical support for further research into the etiological mechanisms but also offer valuable reference points for the clinical use of Metformin in treating NEU and BID, and for exercising caution in its use among patients with ADHD and INS.
Indexed as
Identifiers
40531218What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.